Payment overview · 2025
General Payments
$207.66
9 reported records · 7 companies
Healthcare provider profile · identity verified
Rohit Gautam, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · VAN BUREN, ME · NPI 1780994194
Verified facts
What the public records show
CMS Open Payments records show Rohit Gautam, MD received $207.66 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.97 | 22.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.00 | 20.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $28.29 | 13.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $27.94 | 13.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.55 | 12.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.48 | 9.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.43 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.66 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 44 |
| Losartan Potassium | Losartan Potassium | 111 | 44 |
| Omeprazole | Omeprazole | 105 | 35 |
| Gabapentin | Gabapentin | 79 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 26 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Furosemide | Furosemide | 58 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 40 |
| Metformin Hcl | Metformin Hcl | 56 | 23 |
| Ibuprofen | Ibuprofen | 52 | 14 |
| Alendronate Sodium | Alendronate Sodium | 50 | 18 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Ozempic | Semaglutide | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 46 | 22 |
| Lisinopril | Lisinopril | 45 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | 17 |
| Ezetimibe | Ezetimibe | 37 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 13 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | 11 |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 11 |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.66 · 9 records | ABBVIE INC. | AIRSUPRA, Azstarys, Cologuard Collection Kit, JASCAYD, Ozempic, QULIPTA, Rybelsus, TERIPARATIDE, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error